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Abstract
We demonstrate photothermal optical coherence tomography (OCT) imaging in highly scattering
human breast tissue ex vivo. A 120 kHz axial scan rate, swept-source phase-sensitive OCT system
at 1300 nm was used to detect phase changes induced by 830 nm photothermal excitation of gold
nanoshells. Localized phase modulation was observed 300–600 μm deep in scattering tissue using
an excitation power of only 22 mW at modulation frequencies up to 20 kHz. This technique enables
integrated structural and molecular-targeted imaging for cancer markers using nanoshells.
Optical coherence tomography (OCT) is a powerful tool for assessing tissue architectural
morphology [1]. It enables three-dimensional (3D) imaging with resolutions approaching that
of histopathology but can be performed in vivo and in real time without the need to remove
and process specimens. Conventional OCT imaging is based on contrast from spatial variations
in tissue scattering. The use of exogenous contrast agents would allow targeted imaging of
specific cells, receptors, or functional processes. OCT contrast enhancement has been
demonstrated using scattering microspheres [2], iron oxide microparticles [3], and
nanoparticles [4–10]. Gold nanoparticles are attractive for OCT owing to their customizable
absorption and scattering properties, biocompatibility, and ease of conjugation to antibodies
and peptides that bind selectively with proteins associated with specific diseases [11]. Gold
nanoparticles have also been used as photothermal therapy agents [12,13]. These characteristics
offer gold nanoparticles “three-in-one” [14] functionality as targeting probes, image contrast
enhancers, and therapeutic agents.
Our group demonstrated phase-sensitive OCT to detect gold nanoshells as contrast agents in
phantoms with high signal-to-noise ratio (SNR) [9]. The technique uses nanoshells with
absorption at 780 nm, where tissue absorption is inherently low. An excitation laser at 808 nm
induces small temperature gradients in sample regions containing nanoparticles. These thermal
variations modulate the sample’s optical path length, which is detected using phase-sensitive
OCT. Photothermal OCT selectively detects regions containing nanoshells, potentially
enabling molecular contrast. Other groups working in parallel demonstrated photothermal OCT
imaging in 3D cell constructs using immunotargeted gold nanospheres [10]. Photothermal OCT
imaging is challenging in tissues where scattering plays an important role. In this Letter, we
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demonstrate the feasibility of photothermal OCT in human breast tissue. By modulating the
thermal excitation beam at high frequencies, localized photothermal phase contrast can be
observed 300–600 μm deep in a tissue using a photothermal modulation power of only 22 mW
at 830 nm.
A swept-source OCT system (Fig. 1) with a buffered Fourier-domain mode-locked (FDML)
laser running at 1310 nm and 120 kHz was used for these studies. The laser tuning range is
~170 nm. Photothermal excitation was performed with an 830 nm single mode laser diode.
Gold nanoshells (Nanospectra Biosciences Inc.) with a peak absorption cross-section at 780
nm (~4×10−10 cm2) consisting of a 120 nm silica core and a 16 nm gold shell were used. The
absorption cross-section is ~3×10−10 cm2 at 1310 nm [15]. Combining the 1310 and 830 nm
light into the same fiber enables the photothermal modulation beam and the OCT imaging
beam to maintain alignment during scanning. The combined beam was scanned with a
galvanometer on the tissue. The 1/e2 spot size was measured to be 25 and 30 μm for 830 and
1310 nm, respectively. The axial resolution was ~8 μm in tissue. The phase detection sensitivity
was measured using an isolated reflector in the sample arm. The phase variation between
consecutive A-lines was measured at the peak reflection position, and the standard deviation
was ~5 mrad. The average photothermal power on the sample was 22 mW with a sine wave
modulation at various frequencies (5, 10, and 20 kHz). The reflected 830 nm light is blocked
by the 1310 nm circulator and does not affect the OCT signal. The small photothermal spot
size enables lower power to be used and the exposed area to cool at a faster rate compared to
our previous phantom experiment [9].
To simulate the accumulation of molecular-targeted nanoshells in pathological tissues, less
than 50 μl of 5×109 ml−1 bare gold nanoshell solution was injected into freshly excised human
breast tissue collected from reduction mammoplasty specimens. This concentration is
consistent with the estimated concentration attainable in tumor tissues [6]. The collected tissue
was “discarded tissue” and not necessary for pathologic diagnosis. Microscopically the
discarded tissue was comprised of fibrofatty tissue with benign breast lobules (terminal duct
lobular unit). The protocol was approved by the IRB at Massachusetts Institute of Technology,
and BIDMC. We appreciate that the use of ex vivo specimens are imperfect approximations to
in vivo imaging; however, it serves to demonstrate the feasibility of these imaging methods in
scattering tissue. Photothermal OCT was performed near the nanoshell injection sites with the
OCT beam focused ~500 μm below the tissue surface. An OCT signal along with a calibration
Mach–Zhender interferometer (MZI) signal was continuously acquired using a 14 bit, 200 MHz
A/D converter. 1667 sample points were acquired per frequency sweep, and a chirped Z
transform was used to obtain amplitude and phase profiles within the top 800 μm imaging range
with 1024 points for each A-scan. The data were acquired over a transverse distance of 2 m
across the tissue with various scanning speeds from 2 to 16 mm/s.
Time-dependent phase curves at each sample depth were obtained over 234 transverse A-lines
[~2 ms acquisition, Fig. 2(d)]. A low-frequency background phase drift was removed using a
sixth-order polynomial fit before a transverse spatial fast Fourier transform (FFT) was
performed to generate phase modulation spectra as a function of frequency. Spectra from four
consecutive depth pixels were averaged to reduce noise [Fig. 2(e)]. First, the phase modulation
amplitude at the photothermal modulation frequency (5, 10, or 20 kHz) was extracted. The
background phase noise level was then obtained by averaging the signal amplitude at
frequencies 1 to 2 kHz higher than the photothermal modulation frequency. A photothermal
image was constructed by subtracting the background from the phase modulation amplitude.
An SNR image was then obtained by normalizing the photothermal image to the standard
deviation of signal in a nanoshell-free region. An SNR threshold of 4 and an OCT intensity
threshold of −40 dB were used to isolate regions containing photothermal signals, which were
superimposed as pseudocolor on the gray scale structural OCT images. A 5×5 pixel mean filter
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was used to smooth the image. Images obtained without photothermal modulation and from a
saline injected specimen were used as controls.
As shown in Figs. 2(b) and 2(c), photothermal OCT can visualize localized accumulation of
nanoshells near the injection site ~300–600 μm below the tissue surface. Phase modulation
was absent in the saline injection controls [Fig. 2(a)] or when there was no photothermal
excitation. In addition, as the modulation frequency increases from 5 to 10 kHz, the
photothermal SNR increases from ~16 to 24 measured at locations marked X in Fig. 2(c),
although the amplitude of the phase modulation decreases from 10.8 to 6.5 (arbitrary unit).
Modulating at higher frequencies allows a lower photothermal modulation signal to be detected
with a relatively high SNR, because the phase noise is lower. Increasing the modulation
frequency to 20 kHz results in a SNR of ~23, although the phase modulation signal decreases
to 3.5. The peak-to-peak phase change is only ~0.1 rad for the 20 kHz modulation [Fig. 2(d)],
corresponding to an optical path length change of ~20 nm. Figure 3 shows images of the phase
modulation signal at scan speeds of 2–16 mm/s using 10 kHz photothermal modulation. The
same threshold was used to determine regions where nanoshells were present. The phase
modulation from nanoshell thermomodulation can be visualized at a beam-scanning speed of
16 mm/s.
These results demonstrate that photothermal OCT is feasible in highly scattering tissues. In
scattering samples, one of the major sources of phase noise is from the microstructural features
in the tissue. Interference speckle also contributes to the background phase noise. However,
the influence from these sources is mainly at low frequency. In addition, the scattering of the
thermal excitation beam results in a larger volume of heated tissue. This reduces the
temperature/phase changes within the focal volume and makes the modulated phase signal
smaller and harder to detect. In this study, several approaches were used to improve the
photothermal phase signal SNR. The most significant is to modulate and detect the phase signal
at a high frequency. The photothermal modulation frequency employed here (5, 10, and 20
kHz) is much higher than the frequency used previously (e.g., 25 Hz) [10]. The 1/f background
phase noise is reduced at frequencies away from the base band, improving the SNR. Modulation
at a higher frequency also improves imaging speed. Previous studies suggest that an optimal
photothermal modulation frequency exists for a given sample and imaging system to achieve
sufficient detection sensitivity [9]. This is critical for in vivo applications where the agent may
be administered systemically and local concentrations are low.
These results also demonstrated that photothermal detection is possible at low power levels,
consistent with future in vivo applications. This is achieved by combining the thermal
modulation and OCT imaging beam into the same optical fiber, focusing to a tight spot.
Compared to previous experiments [9], this significantly reduced the photothermal spot size,
which reduces excitation energy required to generate a strong local phase modulation. The
smaller focal volume also has a rapid thermal relaxation time, minimizing local heat
accumulation in the sample.
One limitation of photothermal OCT is that a high oversampling (>100 transverse samples per
beam diameter at 16 mm/s scanning speed) is needed to extract the phase modulation signal,
limiting the imaging speed. This can be mitigated by acquiring fewer transverse samples (N)
at a cost of reduced SNR (scaled as the square root of N). A balance exists between optimizing
the imaging speed and signal contrast. Another limitation of the current study is that
unconjugated nanoshells were used to simulate the localized accumulation of the contrast
agent. In future studies, we will investigate antibody fragment or peptide marker conjugated
nanoshells for molecularly targeted imaging.
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Fig. 1.
Schematic of photothermal OCT setup. A collinear photothermal excitation beam is coupled
into a swept source OCT imaging system.
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Fig. 2.
Photothermal OCT in human breast tissues ex vivo. (a) No photothermal signal is observed
from control images in saline injected specimen. (b) Phase modulation signal and (c) SNR
images from the nanoshell injected specimen (no excitation, 5, 10, and 20 kHz modulation)
demonstrate localized photothermal signal. (d, e) Time-dependent phase modulation and
frequency spectra corresponding to pixels marked in (c).
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Fig. 3.
Phase-modulation signal images at various beam-scanning speeds ranging from 2 to 16 mm/s
with 10 kHz photothermal modulation.
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